Quick View
| Metric | Current Period | Same Period of Previous Year | YoY |
|---|---|---|---|
| Revenue | ¥2156.4B | ¥2133.8B | +1.1% |
| Operating Income | ¥153.3B | ¥64.0B | +139.6% |
| Profit Before Tax | ¥172.6B | ¥100.1B | +72.4% |
| Net Income | ¥138.1B | ¥78.7B | +75.5% |
| ROE | 8.6% | 5.5% | - |
Executive Summary
The significant improvement in the operating margin was the core feature of the current period’s results, with a clear trend toward profit growth despite limited revenue growth. Revenue was ¥2156.4B (+1.1% YoY), operating income was ¥153.3B (+139.6%), and net income was ¥138.1B (+75.5%). The primary drivers of earnings growth were a decline in the cost-of-sales ratio and the containment of SG&A expenses. The gross margin improved from the previous year to 30.1%, while the SG&A ratio declined to 23.2%. Revenue and profit growth in the Industrial Business and improved profitability in the Medical Business despite lower revenue supported the recovery in company-wide profitability.
Factors Affecting Performance
【Revenue】Revenue was ¥2156.4B, essentially flat at +1.1% YoY. The Industrial Business grew to ¥1367.5B (+5.1%), while the Medical Business declined to ¥788.9B (-5.3%). By region, North America grew +6.9% and Europe grew +9.2%, while Asia declined -9.6%, resulting in divergent regional performance.
【Profit and Loss】Operating income increased significantly to ¥153.3B (+139.6% YoY). The gross margin improved to 30.1% from 27.2% in the previous year, while SG&A expenses decreased to ¥501.0B (-3.0%). Profit before tax was ¥172.6B and net income was ¥138.1B (+75.5%); the decline in financial income (¥38.3B→¥24.9B) partially constrained net income growth. Overall, the company achieved both revenue and profit growth, with the profit growth rate substantially exceeding the revenue growth rate.
Segment Analysis
The Industrial Business generated revenue of ¥1367.5B (63.4% of total revenue, +5.1% YoY), operating income of ¥135.0B (+84.8%), and a 9.9% operating margin, making it the primary contributor to company-wide profit. The Medical Business posted lower revenue of ¥788.9B (36.6% of total revenue, -5.3%), but operating income improved to ¥60.5B (+51.0%) and the operating margin improved to 7.7%, indicating improved profitability despite the revenue decline. The Industrial Business’s high profit growth rate drove consolidated operating income (¥153.3B), while the Medical Business was also affected by business reorganization (changes in segment classification resulting from organizational changes).
Key Financial Metrics
【Profitability】The operating margin was 7.1%, improving 4.1pt from 3.0% in the previous year, while the net profit margin also improved to 6.3% from 3.7%. ROE was 9.2%, up from 6.0% in the previous year.【Cash Flow Quality】Operating Cash Flow (OCF) was ¥176.2B, a significant improvement from negative ¥65.7B in the previous year. OCF was 1.29x net income of ¥138.1B, indicating sound cash support for earnings. However, trade receivables used ¥125.1B of cash and inventories used ¥27.4B, with the increase in working capital weighing on OCF.【Investment Efficiency】Capital expenditures were ¥51.4B, only approximately 0.46x depreciation and amortization of ¥112.5B, indicating restrained replacement investment. Free cash flow, calculated as the sum of OCF and investing cash flow, was ¥177.5B.【Financial Soundness】The equity ratio was 44.2%, improving from 43.0% in the previous year. Cash and cash equivalents were ¥445.8B, while long-term borrowings were ¥739.2B. Operating income covered finance costs of ¥11.4B by approximately 13.4x, indicating ample debt-servicing capacity.
Cash Flow Analysis
OCF was ¥176.2B, a significant improvement from negative ¥65.7B in the previous year. After incorporating non-cash items such as depreciation and amortization of ¥112.5B into profit before tax of ¥172.6B, the subtotal reached ¥194.9B. The increases in trade receivables of ¥125.1B and inventories of ¥27.4B placed pressure on cash flow, while increases in trade payables of ¥33.8B and contract liabilities of ¥26.5B partially offset the impact. Investing cash flow was positive at ¥1.3B. Against capital expenditures of ¥51.4B, proceeds from the sale of shares in affiliated companies and other investments of ¥55.7B and proceeds from business transfers of ¥6.1B contributed positively. Financing cash flow was negative ¥97.9B, primarily reflecting repayment of long-term borrowings of ¥82.4B, dividend payments of ¥21.9B, and share repurchases of ¥15.5B. As a result, cash and cash equivalents increased to ¥445.8B and free cash flow was ¥177.5B. However, excluding proceeds from asset sales, operating cash generation after capital expenditures was approximately ¥124.8B; this level should be emphasized when evaluating the capacity for sustainable shareholder returns.
Quality of Earnings
The current period’s earnings growth was primarily driven by structural factors, namely the improvement in the gross margin (27.2%→30.1%) and the containment of SG&A expenses (-3.0% YoY), with limited reliance on one-off extraordinary gains or losses. Below operating income, financial income declined from ¥38.3B to ¥24.9B, while the equity-method investment gain also declined from ¥7.7B to ¥5.8B, with the contraction in non-operating items partially offsetting net income growth. OCF was 1.29x net income, indicating sound cash support for earnings. However, the accumulation of working capital due to increases in trade receivables and inventories warrants attention regarding the time lag in cash conversion during a period when profit expanded more rapidly than revenue. Comprehensive income was ¥220.4B, exceeding net income of ¥138.1B by ¥82.4B. The fair value change of financial assets measured through other comprehensive income, at ¥71.4B, was the primary difference, indicating capital movements separate from operating earnings.
Earnings Outlook and Guidance
For the next period, the company forecasts revenue of ¥2335.0B (+8.3% YoY) and operating income of ¥165.0B (+7.6%). The forecast assumes a substantial deceleration in operating income growth compared with the current period’s +139.6%, and does not anticipate a sharp improvement in the gross margin or SG&A ratio comparable to that of the current period. Meanwhile, forecast EPS of ¥199.19 is below the current-period result of ¥206.22, and forecast net income is also expected to decline, indicating that operating improvements are not expected to translate directly into net income growth. If the declining trend in financial income and equity-method investment gains continues, it will be important to monitor progress at the profit-before-tax and net-income levels.
Shareholder Returns
The annual dividend is ¥40 per share (¥18 interim and ¥22 year-end), resulting in a payout ratio of approximately 19.4%. In addition to dividend payments of ¥21.9B, the company conducted share repurchases of ¥15.5B, bringing the total return ratio to approximately 27.3%. Based solely on the payout ratio, the level is conservatively below 60%, and payment capacity is strong relative to OCF of ¥176.2B and free cash flow of ¥177.5B. The company has indicated an increase in the forecast dividend to ¥50 per share, implying an expected payout ratio of approximately 25.1% against forecast EPS of ¥199.19.
Risk Factors
-
Lengthening of the working capital cycle: Increases in trade receivables of ¥125.1B and inventories of ¥27.4B are weighing on OCF. If the expansion of sales and orders continues to be accompanied by further working capital accumulation, the ability of cash generation to keep pace with earnings growth will remain a challenge.
-
Concentration of the business portfolio: The Industrial Business accounts for 63.4% of revenue, and segment profit in this business increased +84.8% YoY, making it the central contributor to company-wide earnings growth. Changes in demand in this business therefore have a significant impact on consolidated performance.
-
Restrained capital expenditures and regional demand disparities: Capital expenditures of ¥51.4B were only approximately 0.46x depreciation and amortization of ¥112.5B. In addition, regional revenue trends remain divergent, with Asia declining -9.6% YoY while North America and Europe increased, indicating continued regional differences in demand.
Industry Benchmark (For Reference; Company Analysis)
Industry Benchmark (manufacturing)
Profitability and Returns
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Return on Equity | 9.2% | 10.9% (8.2%–12.7%) | −1.7pt |
| Operating Margin | 7.1% | 8.2% (5.8%–11.7%) | −1.1pt |
| Net Profit Margin | 6.4% | 6.4% (5.1%–9.3%) | −0.0pt |
Return on equity and operating margin are below the industry median, while the net profit margin is approximately in line with the median, placing profitability around the middle of the industry range.
Growth and Capital Efficiency
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Revenue Growth Rate (YoY) | 1.1% | 5.0% (1.2%–11.4%) | −3.9pt |
The revenue growth rate is substantially below the industry median, placing top-line growth toward the lower end of the industry range.
※Source: Company compilation
Key Takeaways from the Financial Results
-
The operating margin improved 4.1pt from the previous year to 7.1%, confirming the emergence of operating leverage driven by gross margin improvement and SG&A containment. The Industrial Business’s profit growth (+84.8%) was the primary driver of company-wide profitability.
-
OCF improved to ¥176.2B, providing sound cash support for net income; however, working capital efficiency has room for improvement due to increases in trade receivables and inventories. The fact that capital expenditures remained below depreciation and amortization should also be monitored.
-
Although the next-period forecast assumes revenue growth and operating income growth, profit attributable to owners of the parent is expected to decline from the current period. Accordingly, trends in non-operating items such as financial income and equity-method investment gains will determine the progress of net income.
Theoretical Share Price (Reference Value)
| Scenario | Theoretical Share Price |
|---|---|
| bear (bearish) | ¥2,316 |
| base (base case) | ¥2,361 |
| bull (bullish) | ¥2,417 |
| Calculation Assumption | Value |
|---|---|
| Book Value Per Share (BPS) | ¥2,422 |
| Adjusted Forecast EPS | ¥215.1 |
| Cost of Equity r | 9.77% (10-year Japanese government bond 2.77% + equity risk premium 6.00% + size premium 1.00%) |
| Residual Income Persistence Factor ω / Explicit Forecast Period | 0.62 / 5 years |
| Assumed Payout Ratio | 25.1% |
| Forecast EPS Confidence Adjustment | ×1.080 (based on the historical guidance achievement rate of peer companies in the same industry) |
| Implied PBR / PER | 0.97x / 11.0x |
Sensitivity: ¥2,295–¥2,430 at cost of equity ±1%; ¥2,358–¥2,362 at ω±0.1.
Notes:
- Because forecast ROE is below the cost of equity, the theoretical value will be below book value per share.
(Calculation model: Residual Income Model (Ohlson-type with an explicit 5-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated values based solely on publicly disclosed data; these are not forecasts of the market share price or recommendations of specific investment actions and do not predict or guarantee future share prices.)
This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the company based on publicly disclosed earnings data. Investment decisions should be made at your own discretion and responsibility, after consulting with a professional as necessary.
---End of Report---